聚合物胶束紫杉醇对比溶剂型紫杉醇一线治疗晚期非小细胞肺癌的III期随机研究
该开放标签、随机、多中心III期试验纳入448例IIIB-IV期NSCLC患者,按2:1随机接受pm-Pac+顺铂或sb-Pac+顺铂治疗。pm-Pac组IRC评估ORR显著提高(50% vs 26%,P<0.0001),中位PFS显著延长(6.4 vs 5.3个月,HR 0.63,P=0.0001),治疗相关严重不良事件发生率显著更低(9% vs 18%,P=0.0090),中位OS无显著差异。
要点
- pm-Pac+顺铂较sb-Pac+顺铂显著提高IRC评估ORR(50% vs 26%)。
- pm-Pac组中位PFS显著延长(6.4 vs 5.3个月,HR 0.63)。
- pm-Pac组治疗相关严重不良事件发生率显著更低(9% vs 18%)。
核心结论
- pm-Pac联合顺铂一线治疗晚期NSCLC较sb-Pac联合顺铂显著改善ORR和PFS,且安全性更优,可作为治疗选择。
研究设计与样本
- 开放标签、随机、多中心III期试验,纳入448例IIIB-IV期NSCLC患者,按2:1随机分组。
- pm-Pac组300例接受pm-Pac(230 mg/m2)联合顺铂(70 mg/m2),每3周一次共6周期;若第一周期后未观察到预设毒性,从第二周期起pm-Pac剂量升至300 mg/m2。
- sb-Pac组148例接受sb-Pac(175 mg/m2)联合顺铂(70 mg/m2)。
- 主要终点为独立评审委员会(IRC)评估的客观缓解率(ORR)。
主要发现
- IRC评估ORR在pm-Pac组为50%,sb-Pac组为26%(率比1.91,P<0.0001)。
- 亚组分析显示鳞癌和非鳞癌组织学类型中pm-Pac组ORR均 consistently 更高。
- IRC评估中位PFS在pm-Pac组为6.4个月,sb-Pac组为5.3个月(HR 0.63,P=0.0001)。
- 中位OS两组间无显著差异。
- 治疗相关严重不良事件发生率pm-Pac组为9%,sb-Pac组为18%(P=0.0090)。
关键数值与推荐
- pm-Pac剂量为230 mg/m2,顺铂70 mg/m2,每3周一次共6周期;符合条件者pm-Pac可升至300 mg/m2。
- sb-Pac剂量为175 mg/m2,顺铂70 mg/m2。
- 主要终点ORR由IRC评估。
临床怎么用
- 对于晚期NSCLC一线治疗,pm-Pac联合顺铂可考虑作为sb-Pac联合顺铂的替代方案,尤其关注ORR和PFS获益及严重不良事件减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polymeric micellar paclitaxel (pm-Pac) is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel. We aimed to compare the efficacy and safety between pm-Pac plus cisplatin and solvent-based paclitaxel (sb-Pac) plus cisplatin in advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 448 stage IIIB to IV NSCLC patients were randomly assigned (2:1) to receive six 3-week cycles of either pm-Pac (230 mg/m2) plus cisplatin (70 mg/m2; n = 300), followed by dose escalation of pm-Pac to 300 mg/m2 from the second 3-week cycle if prespecified toxic effects were not observed after the first cycle, or sb-Pac (175 mg/m2) plus cisplatin (70 mg/m2; n = 148). The primary end point was objective response rate (ORR) assessed by independent review committees (IRCs). The secondary end points included IRC-assessed progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Patients in the pm-Pac-plus-cisplatin group showed significant improvements in IRC-assessed ORR compared with those in the sb-Pac-plus-cisplatin group (50% versus 26%; rate ratio 1.91; P < 0.0001). Additionally, subgroup analysis showed that a higher ORR was consistently observed in both squamous and nonsquamous histological types. IRC-assessed median PFS was significantly higher in the pm-Pac-plus-cisplatin group than in the sb-Pac-plus-cisplatin group (6.4-month versus 5.3-month; hazard ratio 0.63; P = 0.0001). Median OS was not significantly different between the two groups. The incidence of treatment-related serious adverse events (9% versus 18%; P = 0.0090) was significantly lower in the pm-Pac-plus-cisplatin group than in the sb-Pac-plus-cisplatin group. CONCLUSION: Pm-Pac plus cisplatin yielded superior ORR and PFS along with a favorable safety profile and should become an option for patients with advanced NSCLC. CLINICAL TRIAL IDENTIFIER: ClinicalTrials.gov NCT02667743; https://clinicaltrials.gov/ct2/show/NCT02667743.
引用
- Shi M, Gu A, Tu H, et al. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. Ann Oncol. 2020. PMID: 33130217. doi:10.1016/j.annonc.2020.10.479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。